[OH:1][C:2]1[C:7](=[O:8])[NH:6][C:5]([CH2:9][C:10]2[CH:15]=[CH:14][CH:13]=[CH:12][C:11]=2[C:16]2[CH:21]=[CH:20][CH:19]=[C:18]([CH3:22])[CH:17]=2)=[N:4][C:3]=1[C:23]([O:25]C)=[O:24].O.[OH-].[Li+].C1COCC1>O>[OH:1][C:2]1[C:7](=[O:8])[NH:6][C:5]([CH2:9][C:10]2[CH:15]=[CH:14][CH:13]=[CH:12][C:11]=2[C:16]2[CH:21]=[CH:20][CH:19]=[C:18]([CH3:22])[CH:17]=2)=[N:4][C:3]=1[C:23]([OH:25])=[O:24]In a round-bottomed flask, methyl 5-hydroxy-2-((3′-methylbiphenyl-2-yl)methyl)-6-oxo-1,6-dihydropyrimidine-4-carboxylate (30 mg, 85.6 μmol) and lithium hydroxide hydrate (6.5 mg, 155 μmol) were combined with THF (2 ml) and water (1 ml) to give a colorless solution. The mixture was stirred at 50° C. for one day. Amberlyst (15, ion exchange resin) was added, the mixture was stirred for 10 min, filtered and evaporated to dryness. Trituration with EtOAc and hexanes provided the title compound as a white solid (0.011 g; 34%). LCMS: m/z=337 (MH+) 90% pure.
読み込み中…
